午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Pretomanid Impurity
Pretomanid Impurity
  • Pretomanid Impurity
  • Pretomanid Impurity
  • Pretomanid Impurity
  • Pretomanid Impurity
  • Pretomanid Impurity

Pretomanid Impurity NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-06-18

Product Details

Product Name: Pretomanid Impurity CAS No.: 1131004-99-3
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/06/18

Pretomanid Impurity1131004-99-3

Article illustration

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

    • Product Number: P109002
      English Name: Pretomanid Impurity 2
      English Alias: (S)-3-nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
      CAS Number: 1131004-99-3
      Molecular Formula: C??H??F?N?O?
      Molecular Weight: 359.26

    • Product Advantages

    • High-purity standard:HPLC purity ≥99.0%, with structure confirmed by multiple methods including 1H NMR, 13C NMR, HRMS (high-resolution mass spectrometry), and elemental analysis, meeting the strict requirements of FDA and EMA for impurity reference standards.

    • Reliable stability:Stable for 36 months when stored at -20°C in the dark, and with a degradation rate <1% after heating at 60°C for 48 hours in solution (e.g., acetonitrile-water system), suitable for long-term storage and high-temperature accelerated testing.

    • Precise chiral configuration:Defined (S)-configuration with optical purity ≥99.5% (determined by chiral HPLC), enabling accurate tracking of nitro positional isomerization impurity risks in Pretomanid synthesis.


    • Applications

    • Pharmaceutical quality control:Used for LC-MS/MS detection of Impurity 2 in Pretomanid APIs and formulations, controlling its content ≤0.1% in accordance with ICH Q3B standards to ensure compliance with genotoxic impurity (GTIs) screening requirements.

    • Synthesis process optimization:In nitroimidazole cyclization reactions, monitoring impurity content (e.g., reducing impurity from 0.8% to 0.1% when reaction temperature decreases from 50°C to 30°C) optimizes nitration reagent dosage and reaction time to reduce by-product formation.

    • Analytical method development:Serves as a structural analog impurity reference standard for establishing specific detection methods, such as ultra-performance liquid chromatography-diode array detection (UPLC-DAD), to achieve baseline separation from the main peak (resolution >2.0).

    • Toxicological research support:Provides samples for evaluating the potential toxicity of nitro positional isomerization impurities, facilitating in vitro mammalian cell gene mutation tests (e.g., HPRT test) to meet regulatory requirements for impurity safety assessment.


    • Background Description
      Pretomanid Impurity 2 is a positional isomer impurity introduced during Pretomanid synthesis due to insufficient site selectivity in nitration reactions. The nitro group at the 3-position (instead of the 2-position in the parent drug) may affect the binding mode of the drug to Mycobacterium tuberculosis targets, increasing metabolic toxicity risks. According to the ICH M7(R1) guideline, impurities with nitroaromatic structures require genotoxicity assessment, making strict control of this impurity a key aspect of Pretomanid quality research. Current industry standards set the individual impurity limit at ≤0.1% with reference to ICH Q3A.

    • Research Status

    • Innovations in detection technology:UPLC-MS/MS is used with a C18 column (1.7μm, 2.1×100mm) and 0.1% formic acid aqueous solution-acetonitrile (gradient elution) as the mobile phase. The limit of detection (LOD) can reach 0.01ppm under multiple reaction monitoring (MRM) mode, suitable for trace impurity quantification.

    • Formation mechanism research:This impurity mainly originates from the electrophilic substitution selectivity of nitration reagents (e.g., nitric acid-acetic anhydride system). The proportion of 3-nitro substitution products increases significantly under strongly acidic conditions (pH <2) or high temperatures (>40°C). Using weakly acidic nitration conditions (e.g., potassium nitrate-trifluoroacetic acid) and low-temperature (0-5°C) reactions can reduce impurity formation by over 85%.

    • Safety evaluation progress:In vitro Ames tests showed no mutagenicity at concentrations ≤200μg/dish, but renal tubular epithelial cell vacuolization was observed in high-dose groups (100mg/kg) during a 28-day repeated dosing test in rats, suggesting that reasonable limits (e.g., ≤0.08%) should be set based on toxicological data.

NOTE!

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 






Company Profile Introduction

1. Drug standards and drug impurity reference substances: provide more than 20,000 kinds of spot impurity reference substances, with sufficient supply and same-day delivery. We have a professional R&D team and comprehensive quality control testing to ensure product quality and reliability. 2. Customized synthesis of impurities and new molecules: Quickly respond to the customized needs of CDE impurities, stably supply impurities that have established quality standards, and provide customized synthesis services for new compounds in the research and development of innovative drugs. 3. Preparation and separation of unknown impurities: With a professional impurity preparation and separation technical team and SFC preparation and separation instruments, we can solve the problems of impurity preparation in complex projects. 4. Process development of new drug intermediates: provide the supply of new drugs and new molecular impurities, process optimization services, as well as the screening and impurity analysis of commercialization routes. 5. Peptide synthesis: Provide customized peptide synthesis services, and cover all kinds of degradation impurities and process impurities generated in the research and development of peptide drugs. At the same time, it provides comprehensive structural confirmation data and customized testing services.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1g
VIP2Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-07-24
$41.00/5mg
VIP5Y
TargetMol Chemicals Inc.
2025-07-27
$0.00/1g
VIP1Y
Wuhan Circle Star Chem-medical Technology Co.,Ltd
2025-01-20
INQUIRY